Biochemistry, Lupus Anticoagulant


Article Author:
Zoaib Rasool


Article Editor:
Vivekanand Tiwari


Editors In Chief:
Ishwarlal Jialal


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Abbey Smiley
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
6/22/2019 8:12:39 AM

Introduction

The term 'lupus anticoagulant' is a misnomer as it is neither only found in lupus, nor is it mainly associated with bleeding. The term LA was first coined to describe the phenomenon of plasma samples from patients with systemic lupus erythematosus (SLE) that failed to clot within an appropriate time.[1] Lupus anticoagulant (LA) is one the of antiphospholipid antibodies, which also include anticardiolipin (aCL) antibody and anti-beta2-glycoprotein (GP) I  antibodies. LA are heterogenous autoantibodies, predominantly IgG, and IgM isotypes that specifically target the phospholipid-protein component of the cell membrane. LA interferes and prolongs clotting process, which is a risk factor for arterial and/or venous thrombosis with complications such as stroke, transient ischemic strokes, acquired thrombophilia, and pregnancy loss.  Furthermore, LAs may be transitory in the setting of certain medications or infections and thus have also present in asymptomatic patients.[2] Testing for LAs is essential in patients with hypercoagulable states and antiphospholipid syndromes.[3]

Fundamentals

Lupus anticoagulants are a heterogeneous class of immunoglobulins that specifically target the epitopes of the negatively charged phospholipid binding protein of cell membrane, prothrombin, and beta2-glycoprotein I (beta2-GPI) which inhibit phospholipid-dependent coagulation in vitro.[4]  Therefore, ironically, LA is associated with arterial and venous thrombosis rather than bleeding. Thrombotic risk due to LA is considered to be strongest compared to anti–beta-glycoprotein I or anticardiolipin antibodies.[5] Moreover, the risk of thrombosis correlates strongly with LA due to beta2-glycoprotein I (beta2-GPI) autoantibodies than antiprothrombin autoantibodies.[6][7] These immunoglobins may develop spontaneously due to medications, infections, or as a consequence of autoimmune diseases such as lupus erythematosus.[8] Infections such as EBV, syphilis, and hepatitis C increase the likelihood of acquired lupus anticoagulant.

Issues of Concern

Lupus anticoagulant is estimated to be present in 2 to 4% of the general population, but true prevalence is unclear. Estimates are that lupus anticoagulant is present in 15 to 34% of patients with systemic lupus erythematosus. LA Incidence increases with age and female sex.[9] Laboratory detection of LA is challenging due to the heterogenicity of antibodies and epitopes on protein in the phospholipids. Thus, there is no single LA test capable of detecting all LAs. Clinical laboratories have shown variance in sensitivity and specificity. There are many different mechanisms proposed for this variance, including adequate plasma preparation that is not platelet poor and dilutional effects of mixing studies that impact detection of LA. Laboratory diagnosis of LA may be difficult but could allow for the optimal duration of therapy as the risk of occurrence and recurrence venous/arterial thromboembolism are high.[10] Initial positive testing for LA activity should be repeated after at least 12 weeks to confirm its persistence as it could be falsely positive due to some drugs and infections.

Cellular

Lupus anticoagulants are predominantly IgG and IgM autoantibodies that bind to negatively charged phospholipid-binding proteins, prothrombin, or beta2-glycoprotein I (beta2-GPI).[11] Phospholipid-dependent coagulation is prolonged with LA; hence, the observed phenomenon in-vitro and ultimately leads to thrombus formation. There are many different mechanisms proposed for the induction of anti-phospholipid binding proteins, including infections, oxidative stress, and major stress such as surgery or trauma. Increasing evidence support the notion that oxidation unmasks critical antiphospholipid syndrome b-cell epitopes.[12] All of these stressors combined help expose the phospholipids that eventually allows for antibodies to attach; this, in turn, leads to intravascular coagulation and thrombus formation.

Testing

There is no single test to detect lupus anticoagulant. However, a sequential nonstandard test exists that helps determine whether a patient has lupus anticoagulant.

1) Initial testing, which is also called the screening test, involves the use of one or more phospholipid-containing reagents. This test usually uses PTT, LA-sensitive PTT or dilute Russell viper venom test (DRVVT). These tests allow measuring the time it takes (in seconds) for a plasma sample to clot and which due to lupus anticoagulant gets prolonged beyond the upper limit of the reference.

2) Upon observation of prolongation in the above test, a mixing study is next. A mixing study is a mixture of an equal volume of patient’s plasma with “normal” pooled plasma, and a PTT or preferably, DRVVT is performed on this mixture. Mixing study eliminates the possibility that prolongation is due to coagulation factor deficiency and confirms that an inhibitor is present. Mixing study also confirms that inhibitor is directed towards negatively charged phospholipid and not specific coagulation factor. The mixing study fails to correct the prolonged coagulation test if it is due to LA.

3) Additionally, a confirmatory test involves the addition of excess phospholipid to shorten or correct the prolonged coagulation test. Thus lupus anticoagulant is characterized by the correction of prolonged clotting time with added phospholipid and not with control plasma. Many different sources of phospholipid are available, including aged platelets and synthetic phospholipids in the combination of APTT or DRVVT.

The International Society of Thrombosis and Hemostasis (ISTH) states that four criteria must be met to confirm the presence of lupus anticoagulant.

  1. (Screening test) Prolonged result in one of two coagulation tests that are phospholipids dependent such as PTT-LA or DRVVT
  2. (Mixing study) observe the prolonged result on mixing study
  3. (Confirmatory test) Lack of prolonged time when adding additional phospholipids
  4. Ruling out other coexisting coagulation factor inhibitor such as factor VII.

Lupus anticoagulant testing is often done simultaneously with cardiolipin antibody and anti-beta2-glycoprotein I antibodies when the antiphospholipid syndrome is suspected.[13] Despite current guidelines and recommendations, many issues remain including the lack of uniformity among laboratories with testing protocols and procedures that overall impact result interpretations. Integrated test that consists of only screening and the confirmatory test has been used to detect LA with convenience and less time consumption. However, further investigation into the accuracy of these tests is still needed.[14] In conclusion, LA diagnosis remains challenging and needs standardization.

Clinical Significance

Studies have shown lupus anticoagulant, compared to other antibodies, more strongly correlates with pregnancy morbidity and thrombosis.[15] The presence of LA is suspected initially in a large number of cases, only due to an isolated prolongation of PTT. In such cases, followup is by the mixing study and the confirmatory test, as explained above. [16] It is worth noting that while aCL and anti-beta2-GP I antibodies are seldom affected by anticoagulation, LA activity could be labeled falsely positive by anticoagulants such as warfarin, heparin, or newer anticoagulants including rivaroxaban, apixaban or dabigatran.[17] The antiphospholipid syndrome due to lupus anticoagulant should be further investigated and differentiated from other inherited and acquired thrombophilias as well. The differential diagnosis for a patient with arterial or venous thrombus should be kept in mind which includes paroxysmal nocturnal hemoglobinuria, heparin-induced thrombocytopenia (HIT), myeloproliferative neoplasms, factor V Leiden mutation, protein C and S deficiency, thrombotic thrombocytopenia purpura, vasculitis hemolytic uremic syndrome and disseminated intravascular coagulation.

Once a patient has been diagnosed with LA causing antiphospholipid syndrome per the Sapporo criteria (also known as Sydney criteria ).[18][19] Treatment guidelines are similar to antiphospholipid syndrome caused by other implicated antibodies. The mainstay treatment for antiphospholipid syndrome, including lupus anticoagulant in patients with acute thromboembolism is anticoagulation. Warfarin is the mainstay treatment and recommended over direct oral anticoagulant (DOAC) for secondary prevention.[20] Since LA is associated with obstetric complications, heparin is recommended over warfarin during pregnancy. 


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Biochemistry, Lupus Anticoagulant - Questions

Take a quiz of the questions on this article.

Take Quiz
A 23-year-old patient presents to the clinic for follow up appointment. She was diagnosed with lupus anticoagulant after a blood clot and has been taking warfarin. Which of the following is associated with the lupus anticoagulant?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old female is referred to hematologist due to positive Russell viper venom test performed by her primary provider. The patient states she has had multiple pregnancies without any complications. What condition is indicated by a positive Russell viper venom test?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 32-year-old African-American female presents to the clinic after recently being diagnosed with systemic lupus erythematosus. The patient is currently on hydroxychloroquine with no active complaints. She takes warfarin without any complications due to a history of deep venous thrombosis and positive lupus anticoagulant. Her last INR was 2.3. The patient wishes to become pregnant. Which of the following therapy adjustment, if any, is warranted?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 23-year-old otherwise healthy female presents to the campus health center because for left knee pain for the past two days. Patient denies any recent travels, trauma or any similar previous episodes. On examination, she has a positive Homan sign on the left knee. Doppler ultrasound reveals a deep venous thrombosis. Labs are all normal except an elevated aPTT. Which of the following test should be performed to confirm the diagnosis of lupus anticoagulant?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 32-year-old G2P0 female presents to the clinic for a follow-up appointment. The patient confirmed pregnancy with a home testing device one week ago. Transvaginal ultrasound in the office reveals embryo with an estimated gestational age of 8 weeks. Patient report two previous miscarriages with each less than ten weeks. The patient is concerned about having another miscarriage. On physical exam, the patient has livedo reticularis. Which of the following is the most important test to be performed during this visit?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 34-year-old male follows up in a clinic for evaluation of a prolonged aPTT. A mixing study was performed that resulted in a failure to correct prolongation. However, the addition of more phospholipid corrects the prolongation. Which of the following is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An 18-year-old female presents to the clinic due to sore throat. She also reports a low-grade fever along with dysphonia. Physical examination is significant for hepatosplenomegaly. Mononucleosis heterophil antibody was found to be positive along with a prolonged aPTT. The patient is advised to avoid contact sports. Which of the following can be present transiently with mononucleosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Biochemistry, Lupus Anticoagulant - References

References

Simanek R,Panzer S,Lechner K,Pabinger I, Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Annals of hematology. 2007 Oct;     [PubMed]
Hell L,Ay C,Posch F,Gebhart J,Koder S,Mackman N,Pabinger I,Thaler J, Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. Annals of hematology. 2019 Feb;     [PubMed]
Favaloro EJ,Mohammed S,Curnow J,Pasalic L, Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology. 2019 Apr;     [PubMed]
Love PE,Santoro SA, Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Annals of internal medicine. 1990 May 1;     [PubMed]
Bertolaccini ML,Amengual O,Andreoli L,Atsumi T,Chighizola CB,Forastiero R,de Groot P,Lakos G,Lambert M,Meroni P,Ortel TL,Petri M,Rahman A,Roubey R,Sciascia S,Snyder M,Tebo AE,Tincani A,Willis R, 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity reviews. 2014 Sep     [PubMed]
Jennings I,Kitchen S,Woods TA,Preston FE,Greaves M, Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thrombosis and haemostasis. 1997 May;     [PubMed]
Tripodi A, Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clinical chemistry. 2007 Sep;     [PubMed]
Dembitzer FR,Ledford Kraemer MR,Meijer P,Peerschke EI, Lupus anticoagulant testing: performance and practices by north american clinical laboratories. American journal of clinical pathology. 2010 Nov;     [PubMed]
Arnout J, Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thrombosis and haemostasis. 2001 Jul;     [PubMed]
Urbanus RT,Siegerink B,Roest M,Rosendaal FR,de Groot PG,Algra A, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. The Lancet. Neurology. 2009 Nov;     [PubMed]
Arachchillage DR,Efthymiou M,Mackie IJ,Lawrie AS,Machin SJ,Cohen H, Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thrombosis research. 2015 Feb;     [PubMed]
Galli M,Luciani D,Bertolini G,Barbui T, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003 Mar 1     [PubMed]
de Laat HB,Derksen RH,Urbanus RT,Roest M,de Groot PG, beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004 Dec 1     [PubMed]
Devreese K,Peerlinck K,Hoylaerts MF, Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010 Jan 28     [PubMed]
Passam FH,Rahgozar S,Qi M,Raftery MJ,Wong JW,Tanaka K,Ioannou Y,Zhang JY,Gemmell R,Qi JC,Giannakopoulos B,Hughes WE,Hogg PJ,Krilis SA, Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood. 2010 Sep 16     [PubMed]
Jacobsen EM,Barna-Cler L,Taylor JM,Triplett DA,Wisløff F, The Lupus Ratio test--an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants--ISLA 5. Thrombosis and haemostasis. 2000 May     [PubMed]
Pengo V,Tripodi A,Reber G,Rand JH,Ortel TL,Galli M,De Groot PG, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of thrombosis and haemostasis : JTH. 2009 Oct     [PubMed]
Tripodi A, To mix or not to mix in lupus anticoagulant testing? That is the question. Seminars in thrombosis and hemostasis. 2012 Jun     [PubMed]
Bobba RS,Johnson SR,Davis AM, A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value? The Journal of rheumatology. 2007 Jul     [PubMed]
Miyakis S,Lockshin MD,Atsumi T,Branch DW,Brey RL,Cervera R,Derksen RH,DE Groot PG,Koike T,Meroni PL,Reber G,Shoenfeld Y,Tincani A,Vlachoyiannopoulos PG,Krilis SA, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and haemostasis : JTH. 2006 Feb     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pathology-Chemistry. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pathology-Chemistry, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pathology-Chemistry, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pathology-Chemistry. When it is time for the Pathology-Chemistry board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pathology-Chemistry.